首页> 美国卫生研究院文献>Stem Cell Research Therapy >Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats
【2h】

Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats

机译:人脐带来源的间充质干细胞通过抑制NLRP3炎性体介导的2型糖尿病大鼠的炎症改善胰岛素抵抗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundInsulin resistance is one of the most common and important pathological features of type 2 diabetes (T2D). Recently, insulin resistance is increasingly considered to be associated with systemic chronic inflammation. Elevated levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1β in blood are predictive indicators of the development of T2D. Mesenchymal stem cell (MSC)-based therapies have been proven to have potential immunomodulation and anti-inflammatory properties through their paracrine effects; however, the mechanism for the anti-inflammatory effect of MSCs in enhancing insulin sensitivity is still uncertain.
机译:背景胰岛素抵抗是2型糖尿病(T2D)最常见和重要的病理特征之一。最近,越来越多地认为胰岛素抵抗与全身性慢性炎症有关。血液中肿瘤坏死因子(TNF)-α和白介素(IL)-1β的水平升高是T2D发生的预测指标。基于间充质干细胞(MSC)的疗法已被证明具有旁分泌作用,具有潜在的免疫调节和抗炎特性。然而,MSC增强胰岛素敏感性的抗炎作用的机制仍不确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号